Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report)’s stock price traded up 4.5% on Monday . The company traded as high as $0.4748 and last traded at $0.4596. 1,200 shares traded hands during trading, a decline of 87% from the average session volume of 9,527 shares. The stock had previously closed at $0.44.
Defence Therapeutics Price Performance
The business has a fifty day moving average of $0.47 and a 200-day moving average of $0.52.
Defence Therapeutics Company Profile
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
Featured Stories
- Five stocks we like better than Defence Therapeutics
- Buy this Gold Stock Before May 15th, 2026
- America’s 1776 happening again
- J.P. Morgan is betting on this coin
- Central banks just did something they haven’t done since 1967
- My Epstein Story
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
